Lapointe, Réjean

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 351

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H. (2019) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersViral Infections and Immunology Research

Cited by 224

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications

Cancer Immunotherapy and BiomarkersRenal Transplantation Outcomes and Treatments

Cited by 109

Phenotypic characterization and functional analysis of human tumor immune infiltration after mechanical and enzymatic disaggregation

Grange, C., Létourneau, J., Forget, M.-A., Godin-Ethier, J., Martin, J., Liberman, M., Latour, M., Widmer, H., Lattouf, J.-B., Piccirillo, C. A., et al. (2011) · Journal of Immunological Methods

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 29

The WT hemochromatosis protein HFE inhibits CD8+ T‐lymphocyte activation

Reuben, A., Phénix, M., Santos, M. M., & Lapointe, R. (2014) · European Journal of Immunology

Iron Metabolism and DisordersT-cell and B-cell Immunology

Cited by 21